Hospital and Internal Medicine Podcast podcast

Heart Failure with Preserved Ejection Fraction (Diastolic CHF) and SGLT-2 Inhibitor Therapy

0:00
11:32
Rewind 15 seconds
Fast Forward 15 seconds

The double-blind, randomized phase III EMPEROR-Preserved trial showed a benefit of the sodium-glucose cotransporter-2 (SGLT2) inhibitor empagliflozin in patients with heart failure with preserved ejection fraction (HFpEF).

Now let us dig a bit more into those headlines.

 

More episodes from "Hospital and Internal Medicine Podcast"